The Leukemia & Lymphoma Society (LLS) has handed Lexington, MA-based Curis $4 million to support early development of two of the company's drugs for blood cancers. Curis' drug, CUDC-907, is an oral small molecule dual Pi3K and HDAC inhibitor for patients with B-cell lymphoma and multiple myeloma, the company said in a release. LLS said it would pay for half of the drug's development costs, up to $4 million, and in return will receive milestone payments from Curis if the developer commercializes the drug. "LLS's capital commitment to this program, along with their extensive knowledge of hematological malignancies, will be important resources as we seek to advance this promising first-in-class molecule," Curis CEO Dan Passeri said in a statement. Curis release | Article